Transformation of Castleman’s Disease into Follicular Dendritic Cell Sarcoma, Presenting as an Asymptomatic Intra-abdominal Mass

Soon Oh Hwang, Tae Hoon Lee, Sang Ho Bae1, Hyun Deuk Cho2, Kang Hyug Choi, Sang-Heum Park, Chang Ho Kim1 and Sun-Joo Kim

Departments of Internal Medicine, General Surgery1, and Pathology2, Soonchunhyang University Hospital Cheonan, Soonchunhyang University College of Medicine, Cheonan, Korea

Follicular dendritic cell (FDC) sarcoma is an extremely rare malignant neoplasm arising from FDCs. The exact origin of FDCs remains unclear; both a hematopoietic lineage origin and a stromal cell derivation have been proposed. Proliferation of FDCs can lead to benign reactive lesions or generate neoplastic conditions. The lesions are most commonly found in lymph nodes and usually involve the head and neck area. Castleman’s disease is a rare non-neoplastic lymphoproliferative disorder. Rare cases of hyaline-vascular Castleman’s disease have been associated with FDC sarcoma, but a clonal relationship has not been convincingly demonstrated. A pathway toward tumor evolution, beginning with hyperplasia and dysplasia of FDCs, has been proposed. Despite this known association between Castleman’s disease and FDC sarcoma, there have only been few reported cases of sarcoma arising as a complication of pre-existing Castleman’s disease, especially in abdominal lesions. We describe here a 51-year-old female with an FDC sarcoma arising from unicentric, hyaline-vascular type Castleman’s disease in an intra-abdominal mass. Pathologically, the lesion showed a series of changes during the process of transformation from Castleman’s disease to FDC sarcoma. (Korean J Gastroenterol 2013;62:131-134)

Key Words: Follicular dendritic cell sarcoma; Castleman’s disease

INTRODUCTION

Follicular dendritic cell (FDC) sarcoma is an extremely rare neoplasm arising from the FDCs of germinal centers.1 FDC sarcoma has a low-to-intermediate risk of recurrence or metastasis, and such events may occur many years after the initial diagnosis.2 Castleman’s disease, which is a rare non-neoplastic lymphoproliferative disorder, is classified into two subtypes according to histological features; a hyaline-vascular type and a plasma cell type.3,4 Hyaline-vascular Castleman’s disease (HVCD) has been identified as a possible predisposing factor for FDC sarcoma in a minority of cases. A pathway toward tumor evolution, beginning with hyperplasia and dysplasia of FDCs, has been proposed.5 Despite this known association between Castleman’s disease and FDC sarcoma, there have been only few reported

Received November 26, 2012. Revised January 28, 2013. Accepted January 31, 2013. This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Tae Hoon Lee, Department of Internal Medicine, Digestive Disease Center, Soonchunhyang University Hospital Cheonan, Soonchunhyang University College of Medicine, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 330-903, Korea. Tel: +82-41-570-3662, Fax: +82-41-574-5762, E-mail: thlee9@schmc.ac.kr

Financial support: None. Conflict of interest: None.
cases of sarcoma arising as a complication of pre-existing Castleman’s disease, particularly in abdominal lesions. To our knowledge, a case showing sequential tissue transformation has been reported once in Korea.

We report an unusual case of sequential transformation of an FDC sarcoma starting from Castleman’s disease which presented as an asymptomatic intra-abdominal mass in a Korean female.

CASE REPORT

A 51-year-old female was referred to our hospital because of a pancreatic mass. The lesion was found during a health-screening abdominal ultrasound scan. The patient’s medical history was unremarkable except for hypertension, and she had no symptoms. Her physical examination was normal. Blood laboratory tests including hemoglobin, erythrocyte sedimentation rate, CRP, γ-globulin and tumor markers, were within normal ranges. Chest and abdominal X-rays had non-specific findings.

On abdominal CT scan, a well-enhanced mass of about 4 cm was detected. The lesion was located in the anterior and superior aspects of the pancreatic head (Fig. 1A). MRI revealed a 4.4-cm heterogeneous high-signal intensity mass on the T2 weighted image at the hepatic hilum. The lesion abutted the caudate lobe of the liver and the pancreas (Fig. 1B). Sequential EUS was performed to determine the origin of the mass, and revealed a 4-cm heterogeneous hypoechoic mass on the anterior portion of the head and body of the pancreas. A pancreatic or liver origin seemed unlikely. On PET-CT, other abnormal findings, such as lymph node enlargement, were not detected. Based on the imaging results, we considered a disease of neuroendocrine origin or a mesenchymal tumor, and surgical exploration was planned to confirm this.

During surgery, a 5-cm tumorous lesion originating from a lymph node was found around the head of the pancreas and portal vein; there was no connection with adjacent organs. The mass was completely removed by surgical excision. Macroscopically, the tumor was partially encapsulated by a membrane. On sectioning, the cut surface showed a pale yellowish-to-brownish homogeneous appearance, with multifocal hemorrhagic spots (Fig. 2). Histopathological analysis of the mass revealed a tumor composed of spindle cells, atypical vesicular nuclei, and eosinophilic cytoplasm, in accordance with Castleman’s disease (Fig. 3). Immunohistochemistry was positive for FDC markers (CD21, CD23, CD68). All other markers investigated (CD20, CD79a, CD3, CD45RO, CD10, CD56, CK, CD30, CD1a, EBV, MPO, S-100 protein)

Fig. 2. Gross findings after surgical resection. The encapsulated mass measured 6.0×5.0×3.0 cm and showed a yellowish-to-brown color with hemorrhagic spots.

Fig. 1. Radiological findings. (A) A 4-cm well-enhancing mass was located around the liver, stomach, and pancreas (enhanced CT). (B) A 4.4-cm highly signal intensity mass lesion was noted in same lesion (MRCP, T2 weighted image).
Hwang SO, et al. Transformation of Castleman’s Disease into Follicular Dendritic Cell Sarcoma

Vol. 62 No. 2, August 2013

Fig. 3. Histological features of the mass (H&E, ×400). Microscopic findings indicated an atrophic germinal center with a penetrating vessel and follicular dendritic cell hyperplasia (A), as well as fascicles of spindle cells with atypical vesicular nuclei and eosinophilic cytoplasm, with admixed lymphocytes (B).

were negative. Pathological findings showed an FDC sarcoma, transformed in a background of focal residual Castleman’s disease.

After surgery, the patient received radiation therapy due to the high risk of recurrence; the therapy consisted of a 4,500 cGy dose over 5 weeks. The patient is currently being monitored and has shown no signs of recurrence at 9 months postoperatively.

DISCUSSION

FDC sarcoma is an extremely rare malignant neoplasm arising from FDCs. It was first described in 1986 by Monda et al. Since then, fewer than 80 cases have been reported in the English language literature. FDC sarcoma affects both sexes equally. The median age of occurrence is 47 years, with a wide range from 14 to 77 years. It can involve both nodal and extranodal sites but has a higher incidence in nodal areas, especially in the head and neck area. About 60% of the cases occur in lymph nodes such as the cervical, axillary, and mediastinal lymph nodes. Also, a wide variety of extranodal sites can be affected, including the tonsils, spleen, liver, gastrointestinal tract, mediastinum, and breast. Intra-abdominal tumor locations can involve the liver, spleen, or pancreas, in addition to the mesenteric or retroperitoneal lymph nodes.

Clinical presentation varies according to the location of the primary tumor. Intra-abdominal FDC sarcomas usually have non-specific symptoms, and a diagnosis is made with a histopathological study. Of the reported FDC sarcomas, 10-20% have been shown to be associated with Castleman’s disease (usually HVCD), which can be concurrent with or precede the sarcoma. Castleman’s disease is a lymphoproliferative disorder of B cells and is also known as angiofollicular lymph node hyperplasia.

The etiology of Castleman’s disease is unclear. Clinically, Castleman’s disease is categorized into three types: a unicentric hyaline-vascular type, a unicentric plasma cell type, and a multicentric plasma cell type. The clinical manifestations of Castleman’s disease range from asymptomatic or localized lymphadenopathy to recurrent forms of generalized lymphadenopathy with severe systemic symptoms. In the present case, Castleman’s disease manifested as a single mass in the intra-abdominal cavity without systemic symptoms and was confirmed as a hyaline-vascular type by histology. Therefore, the patient was thought to represent a case of unicentric HVCD.

Castleman’s disease has been found to be associated with FDC sarcoma, suggesting that it may represent a precursor lesion. Castleman’s disease-related hyperplasia acts on the expression of the p53 gene, leading to FDC dysplasia in the germinal center of the affected lymphoid follicle. However, firm evidence of a clonal relationship between Castleman’s disease and FDC sarcoma is lacking. In the English lan-
ter complete excision due to the high recurrence rate asso-
ciated with Castleman’s disease is a rare disorder, it should be
given due consideration when an intra-abdominal mass is detected in a
patient. In the Korean literature, Lee et al.7 reported one case of paraneoplastic pemphigus asso-
ciated with large and intra-abdominal masses.

Although the optimal treatment for FDC sarcoma is un-
known because of the small number of cases, the current ap-
proach is to apply therapeutic guidelines similar to those
used for high-grade soft tissue sarcomas.17 Complete surgi-
cal resection is the therapy of choice, and the roles of ad-
juvant chemotherapy and radiotherapy are controver-
sial.2,11,16,18 However, chemotherapy or radiotherapy should
be considered in cases with adverse prognosis factors, such as
large tumor size (> 6 cm), intra-abdominal location, pres-
ence of coagulative necrosis, high mitotic count (> 5 per 10
high-power fields), and moderate nuclear pleomorph-
ism.5,11,15,19 Adjuvant radiotherapy was found to have a role
in prolonging disease-free survival.2,11,17 However, adjuvant
chemotherapy has not shown consistent results.17 Local re-
currence occurs in about 40% of cases, and metastases in
28%.5,8,11,16 The mortality rate is about 20%.6,11 In the present
case, we decided to administer adjuvant radiation therapy af-
ter complete excision due to the high recurrence rate asso-
ciated with large and intra-abdominal masses.

In summary, we report an unusual case of an FDC sarcoma
arising from unicentric HVCD in the abdominal cavity. The
case showed sequential pathological changes from Cast-
leman’s disease to FDC sarcoma. Although FDC sarcoma aris-
ing from Castleman’s disease is a rare disorder, it should be
considered when an intra-abdominal mass is detected in a
patient.

REFERENCES

1. Monda L, Warnke R, Rosai J. A primary lymph node malignancy
with features suggestive of dendritic reticulum cell differen-

2. Chan AC, Chan KW, Chan JK, et al. Development of follicular den-
ritic cell sarcoma in hyaline-vascular Castleman’s disease of the

393-398.

4. Casper C. The aetiology and management of Castleman disease
at 50 years: translating pathophysiology to patient care. Br J
Haematol 2005;129:3-17.

VCAM-1 and ELAM-1 in angiofollicular lymph node hyperplasia
(Castleman’s disease): evidence for dysplasia of follicular den-


7. Lee IJ, Kim SC, Kim HS, et al. Paraneoplastic pemphigus asso-
ciated with follicular dendritic cell sarcoma arising from

cell sarcoma and interdigitating reticulum cell sarcoma: a

9. Gaertner EM, Tsokos M, Derringer GA, Neuhauser TS, Arciero C,
Andriko JA. Interdigitating dendritic cell sarcoma. A report of four
cases and review of the literature. Am J Clin Pathol 2001;115:
589-597.

10. Kang TW, Lee SJ, Song HJ. Follicular dendritic cell sarcoma of the
abdomen: the imaging findings. Korean J Radiol 2010;11:239-
243.

11. Chan JK, Fletcher CD, Nayar SJ, Cooper K. Follicular dendritic

cell sarcoma. Clinicopathologic analysis of 17 cases suggesting
a malignant potential higher than currently recognized. Cancer

12. Schwarz RE, Chu P, Arber DA. Extranodal follicular dendritic cell

Intra-abdominal follicular dendritic cell sarcoma. Clin Transl
Oncol 2006;8:837-838.

14. Sze DY, Shelton AA. SIR 2008 annual meeting film panel case:
Castleman disease complicated by follicular dendritic cell

15. Perez-Ordoñez B, Rosai J. Follicular dendritic cell tumor: review of

16. Xie Q, Chen L, Fu K, et al. Podoplanin (d2-40): a new immu-
nohistochemical marker for reactive follicular dendritic cells
and follicular dendritic cell sarcomas. Int J Clin Exp Pathol

Dendritic cell neoplasms: an overview. Am J Hematol 2007;82:
924-928.

18. Youens KE, Waugh MS. Extranodal follicular dendritic cell

19. Low SE, Menasce LP, Manson CM. Follicular dendritic cell sarco-
ma: a rare tumor presenting as an abdominal mass. Int J Surg